We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...

LATE-NC diagnostic criteria improve differentiation from Alzheimer's, addressing challenges in memory-loss syndromes and ...

Researchers from the Genome Center have successfully applied advanced artificial intelligence (AI) genetics models to Parkinson's disease. Researchers identified genetic factors in progression and ...

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

Advance directives and estate planning: Ensuring peace of mind for you and your loved ones.

SaveHealth provides an overview of Alzheimer's disease, including treatment and coping mechanisms for those with the disease ...

One recent analysis found that, over the course of three years, people taking semaglutide (the compound in Ozempic and the weight loss drug Wegovy) were about 40 to 70 percent less likely to be ...

Xenon is one of the six noble gases. Its name derives from the Greek word for “strange”. In medicine, it has been used as an ...

LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD ...

Access to the new Alzheimer's drugs is limited by strict eligibility criteria, long wait times, and a lack of infusion ...

Alzheimer’s disease progression does not stop after plaque clearance; ongoing treatment with LEQEMBI can slow disease progression and prolong the benefits of therapy TOKYO and CAMBRIDGE, Mass., Jan.